WeingartSN, SpencerJ, BuiaS, DuncombeD, Medication safety of five oral chemotherapies: A proactive risk assessment. J Oncol Pract. 2011;7(1):2–6.
2.
AisnerJ.Overview of the changing paradigm in cancer treatment: Oral chemotherapy. Am J Health Syst Pharm. 2007;64(9 suppl 5):S4–7.
3.
LauPM, StewartK, DooleyM.The ten most common adverse drug reactions (ADRs) in oncology patients: Do they matter to you?Support Care Cancer. 2004;12(9):626–633.
4.
BarronTI, ConnollyR, BennettK, FeelyJ, KennedyMJ.Early discontinuation of tamoxifen: A lesson for oncologists. Cancer. 2007;109(5):832–839.
5.
HershmanDL, KushiLH, ShaoT, Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128.
6.
KhandelwalN, DuncanI, AhmedT, RubinsteinE, PegusC.Impact of clinical oral chemotherapy program on wastage and hospitalizations. J Oncol Pract. 2011;7(3 suppl):e25s–e29s.
7.
OwsusuC, BuistDS, FieldTS, Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–555.
8.
RuddyK, MayerE, PartridgeA.Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56–66.
9.
BubaloJ, WardenBA, WiegelJJ, NishidaT, HandelE, SvobodaLM, NguyenL, EdilloPN.Does applying technology throughout the medication use process improve patient safety with antineoplastics?J Oncol Pharm Pract. 2014;20(6):445–460.
10.
KaddisAA.Partial fill strategies for oral oncolytics to reduce waste and drive persistency. Am J Manag Care. 2013;19(1 Spec No): SP26–SP27.
11.
MargolisA, YoungH, LisJ, SchunaA, SorknessCA.A telepharmacy intervention to improve inhaler adherence in veterans with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2013;70(21): 1875–1876.
